<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48610">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473393</url>
  </required_header>
  <id_info>
    <org_study_id>341-13-002</org_study_id>
    <secondary_id>JapicCTI-152937</secondary_id>
    <nct_id>NCT02473393</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety, efficacy and pharmacokinetics of multiple dosesin patients with Bacterial
      Enteritis caused by Clostridium difficile infection(CDI) or Enteric infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the microbiological examination</measure>
    <time_frame>CDI group: screening, Day 4, Day 11 (end of treatment), Enteric infection group: screening, Day 4, Day 8 (end of treatment)</time_frame>
    <description>Judged according to the assessment criteria for the bacterial strain isolated as the causative pathogen based on the data from the microbiological examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of OPS-2071 on Day 4</measure>
    <time_frame>Inpatient: 1 h, 2 h, and 4 h after morning,administration , Outpatient: Once within 12 h after morning administration but before evening</time_frame>
    <description>Cmax, tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The recurrence rate of CDI after multiple doses of OPS-2071</measure>
    <time_frame>Day 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to resolution of diarrhea after multiple doses of OPS-2071</measure>
    <time_frame>CDI group: Day 4, Day 11 (end of treatment), and Day 38. Enteric infection group: Day 4, Day 8 (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of clinical symptoms after multiple doses of OPS-2071</measure>
    <time_frame>CDI group: Day 4, Day 11 (end of treatment), and Day 38. Enteric infection group: Day 4, Day 8 (end of treatment)</time_frame>
    <description>Assess the improvement of clinical symptoms, ie, daily stool count, fecal properties, bloody stool, fever, abdominal pain, nausea, and vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The sensitivity to OPS-2071 of the causative pathogen strain isolated from patients</measure>
    <time_frame>CDI group: screening, Day 11 (end of treatment). Enteric infection group: screening, Day 8 (end of treatment)</time_frame>
    <description>Determine the minimum inhibitory concentration (MIC) of OPS-2071 for the isolated/identified Clostridium difficile (C. difficile) or The strain identified as The causative pathogen of enteric infection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bacterial Enteritis</condition>
  <arm_group>
    <arm_group_label>OPS-2071 50mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPS-2071 50 mg/day：25 mg tablet administered orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPS-2071 100 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPS-2071 100 mg/day：50 mg tablet administered orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPS-2071 200 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPS-2071 200 mg/day：100 mg tablet administered orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPS-2071 400 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPS-2071 tablet</intervention_name>
    <arm_group_label>OPS-2071 50mg/day</arm_group_label>
    <arm_group_label>OPS-2071 100 mg/day</arm_group_label>
    <arm_group_label>OPS-2071 200 mg/day</arm_group_label>
    <arm_group_label>OPS-2071 400 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient provides written, informed consent before the clinical trial is initiated

          -  The patient has distinctive symptoms and findings of bacterial enteritis

          -  The patient has bacterial enteritis with one or more of the following causative
             pathogens either proven or presumed: C. difficile, Salmonella, Campylobacter,
             pathogenic E. coli, and other bacteria estimated to cause bacterial enteritis

          -  The patient and his/her partner are willing to take contraceptive measures from
             initiation of investigational medicinal products (IMPs) to 4 weeks after
             administration of IMPs

        Exclusion Criteria:

          -  The patient has severe or progressive underlying disease or complication, making it
             difficult to ensure safety in the study or proper efficacy assessment

          -  The patient has a current diagnosis or history of convulsive disorders, such as
             convulsion and epilepsy

          -  The patient has a severe hepatic dysfunction

          -  The patient has a severe cardiac dysfunction

          -  The patient has cardiac arrhythmia or congenital or sporadic long QTc syndrome. Or
             the patient is treated with a drug reported to prolong QTc interval

          -  The patient has a moderate or severe renal dysfunction

          -  Women with confirmed or suspected pregnancy or breast-feeding women

          -  Patients judged to be ineligible by the investigator for any other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshitaka Kotobuki</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kanto, region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>June 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
